Shahram Paydar: TXA in Elderly Trauma: A Game-Changer for Endothelial Protection?
Shahram Paydar, Professor of Surgery and Trauma Surgeon, Consultant at Gulf Specialized Hospital, shared on LinkedIn:
“TXA in Elderly Trauma: A Game-Changer for Endothelial Protection? New Evidence Says Yes!
Trauma doesn’t discriminate by age, but outcomes do—especially for our older adults, who make up nearly 25% of admissions yet face steeper morbidity and mortality. Enter tranexamic acid (TXA): We know it’s a staple for bleeding control in TBI and hemorrhage, but a fresh 2025 analysis in J Trauma Acute Care Surg spotlights its extra punch in the ≥55 crowd.
Key findings from this secondary dive into the prehospital TXA-in-TBI database (n=436):
Despite similar injury severity (ISS ~20, head AIS ~3), older patients (mean 66y) showed sky-high admission endothelial biomarkers—thrombomodulin (↑17%), VCAM-1 (↑19%), angiotensin-2 (↑23%)—signaling pre-injury vulnerability.
The kicker?
2g prehospital TXA dampened these markers more dramatically in elders vs. younger folks (e.g., thrombomodulin p<0.00001, VCAM-1 p<0.0002 vs. placebo).
Younger subsets?
Less impact.
Why does this matter?
Endothelial dysfunction fuels the post-trauma inflammatory storm, and elders start from a weaker baseline. TXA’s amplified endothelial “shield” here could blunt hypercoagulability, reduce secondary hits, and—potentially—tip the scales on survival and recovery.
No direct mortality links yet (Level IV evidence), but it’s a clarion call: Standard TXA protocols might pack bigger benefits for our aging trauma wave.
As populations gray, this underscores TXA’s role beyond hemostasis—it’s endothelial insurance for the vulnerable.
Time to tweak protocols? Or wait for RCTs?
What’s your take—ramping up TXA emphasis in elder polytrauma? Share protocols or cases below!”
Title: Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial
Authors: Tanya Anand, Scott McLoud, Lindsay Loss, Karen Minoza, Phillip Jenkins, Susan Rowell, Jack McLean, Bellal Joseph, Martin Schreiber
Read the full article here.
Stay updated with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF